{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:18:37Z","timestamp":1790518717024,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ViroPharma\/Shire Development, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,8]]},"DOI":"10.1093\/cid\/ciy706","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T15:29:28Z","timestamp":1538580568000},"page":"1255-1264","source":"Crossref","is-referenced-by-count":210,"title":["Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study"],"prefix":"10.1093","volume":"68","author":[{"given":"Genovefa A","family":"Papanicolaou","sequence":"first","affiliation":[{"name":"Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda P","family":"Silveira","sequence":"additional","affiliation":[{"name":"The Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia A","family":"Langston","sequence":"additional","affiliation":[{"name":"The Winship Cancer Institute, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Uknis","sequence":"additional","affiliation":[{"name":"Shire Pharmaceuticals, Wayne, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wijatyk","sequence":"additional","affiliation":[{"name":"Shire Pharmaceuticals, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Shire Pharmaceuticals, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"The Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M","family":"Marty","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Villano","sequence":"additional","affiliation":[{"name":"Shire Pharmaceuticals, Wayne, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"key\n\t\t\t\t2019040801002208900_CIT0001","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0004","doi-asserted-by":"crossref","first-page":"1121.e9","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0009","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre","year":"2011","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0011","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jinf.2014.07.001","article-title":"Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients","volume":"69","author":"Mart\u00edn-Gandul","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0013","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0014","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0015","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0017","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0018","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0020","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0021","doi-asserted-by":"crossref","first-page":"e1000275","DOI":"10.1371\/journal.ppat.1000275","article-title":"Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress","volume":"5","author":"Hamirally","year":"2009","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0022","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.77.2.905-914.2003","article-title":"The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress","volume":"77","author":"Krosky","year":"2003","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0024","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","article-title":"Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0025","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","article-title":"Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0026","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0027","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0028","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0029","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0031","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0032","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0033","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/ofid\/ofw172.1834","article-title":"Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients","volume":"3","author":"Maertens","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"key":"key\n\t\t\t\t2019040801002208900_CIT0034","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am J Transplant"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/8\/1255\/28272226\/ciy706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T05:07:38Z","timestamp":1571980058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/8\/1255\/5133438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,10,16]]},"published-print":{"date-parts":[[2019,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy706","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2018,10,16]]}}}